William Blair Issues Negative Estimate for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Arcturus Therapeutics in a research note issued to investors on Thursday, March 13th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings per share of ($1.39) for the quarter, down from their prior estimate of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Other analysts also recently issued research reports about the stock. HC Wainwright dropped their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Canaccord Genuity Group dropped their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Wells Fargo & Company dropped their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Stock Up 0.6 %

Shares of NASDAQ ARCT opened at $14.16 on Monday. The firm’s 50-day moving average price is $16.54 and its 200-day moving average price is $18.24. The company has a market cap of $384.02 million, a PE ratio of -6.38 and a beta of 2.96. Arcturus Therapeutics has a 52-week low of $12.75 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The company had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in Arcturus Therapeutics by 0.8% during the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after purchasing an additional 742 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Arcturus Therapeutics by 5.0% during the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 883 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 1,132 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Arcturus Therapeutics by 7.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after purchasing an additional 1,279 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.